194 related articles for article (PubMed ID: 32619293)
1. Generation of multiepitope cancer vaccines based on large combinatorial libraries of survivin-derived mutant epitopes.
Domínguez-Romero AN; Martínez-Cortés F; Munguía ME; Odales J; Gevorkian G; Manoutcharian K
Immunology; 2020 Oct; 161(2):123-138. PubMed ID: 32619293
[TBL] [Abstract][Full Text] [Related]
2. Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer.
NoeDominguez-Romero A; Zamora-Alvarado R; Servín-Blanco R; Pérez-Hernández EG; Castrillon-Rivera LE; Munguia ME; Acero G; Govezensky T; Gevorkian G; Manoutcharian K
Hum Vaccin Immunother; 2014; 10(11):3201-13. PubMed ID: 25483665
[TBL] [Abstract][Full Text] [Related]
3. Generation of cancer vaccine immunogens derived from Oncofetal antigen (OFA/iLRP) using variable epitope libraries tested in an aggressive breast cancer model.
Martínez-Cortés F; Servín-Blanco R; Domínguez-Romero AN; Munguía ME; Guzman Valle J; Odales J; Gevorkian G; Manoutcharian K
Mol Immunol; 2021 Nov; 139():65-75. PubMed ID: 34454186
[TBL] [Abstract][Full Text] [Related]
4. Generation of cancer vaccine immunogens derived from major histocompatibility complex (MHC) class I molecules using variable epitope libraries.
Servín-Blanco R; Chávaro-Ortiz RM; Zamora-Alvarado R; Martínez-Cortes F; Gevorkian G; Manoutcharian K
Immunol Lett; 2018 Dec; 204():47-54. PubMed ID: 30339819
[TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy of MUC1-derived variable epitope library treatments in a mouse model of breast cancer.
Odales J; Servín-Blanco R; Martínez-Cortés F; Guzman Valle J; Domínguez-Romero AN; Gevorkian G; Manoutcharian K
Vaccine; 2022 Aug; 40(33):4796-4805. PubMed ID: 35788294
[TBL] [Abstract][Full Text] [Related]
6. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo.
Yang Y; Che Y; Zhao Y; Wang X
Int Immunopharmacol; 2019 Apr; 69():279-288. PubMed ID: 30743204
[TBL] [Abstract][Full Text] [Related]
7. Variable epitope library-based vaccines: shooting moving targets.
Pedroza-Roldan C; Charles-Niño C; Saavedra R; Govezensky T; Vaca L; Avaniss-Aghajani E; Gevorkian G; Manoutcharian K
Mol Immunol; 2009 Dec; 47(2-3):270-82. PubMed ID: 19853920
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic DNA vaccine targeting Foxp3
Namdar A; Mirzaei R; Memarnejadian A; Boghosian R; Samadi M; Mirzaei HR; Farajifard H; Zavar M; Azadmanesh K; Elahi S; Noorbakhsh F; Rezaei A; Hadjati J
Cancer Immunol Immunother; 2018 Mar; 67(3):367-379. PubMed ID: 29124314
[TBL] [Abstract][Full Text] [Related]
9. CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors.
Hanson HL; Kang SS; Norian LA; Matsui K; O'Mara LA; Allen PM
J Immunol; 2004 Apr; 172(7):4215-24. PubMed ID: 15034034
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
[TBL] [Abstract][Full Text] [Related]
11. Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: prolonged survival.
Mirshahidi S; Kramer VG; Whitney JB; Essono S; Lee S; Dranoff G; Anderson KS; Ruprecht RM
Vaccine; 2009 Mar; 27(12):1825-33. PubMed ID: 19201387
[TBL] [Abstract][Full Text] [Related]
12. Fowlpox-based survivin vaccination for malignant mesothelioma therapy.
Bertino P; Panigada M; Soprana E; Bianchi V; Bertilaccio S; Sanvito F; Rose AH; Yang H; Gaudino G; Hoffmann PR; Siccardi A; Carbone M
Int J Cancer; 2013 Aug; 133(3):612-23. PubMed ID: 23335100
[TBL] [Abstract][Full Text] [Related]
13. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors.
Kilinc MO; Aulakh KS; Nair RE; Jones SA; Alard P; Kosiewicz MM; Egilmez NK
J Immunol; 2006 Nov; 177(10):6962-73. PubMed ID: 17082611
[TBL] [Abstract][Full Text] [Related]
14. Variable epitope libraries: new vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response.
Charles-Niño C; Pedroza-Roldan C; Viveros M; Gevorkian G; Manoutcharian K
Vaccine; 2011 Jul; 29(32):5313-21. PubMed ID: 21600948
[TBL] [Abstract][Full Text] [Related]
15. A tumor lysate is an effective vaccine antigen for the stimulation of CD4(+) T-cell function and subsequent induction of antitumor immunity mediated by CD8(+) T cells.
Kawahara M; Takaku H
Cancer Biol Ther; 2015; 16(11):1616-25. PubMed ID: 26391871
[TBL] [Abstract][Full Text] [Related]
16. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses.
Karkada M; Weir GM; Quinton T; Sammatur L; MacDonald LD; Grant A; Liwski R; Juskevicius R; Sinnathamby G; Philip R; Mansour M
J Immunother; 2010 Apr; 33(3):250-61. PubMed ID: 20445345
[TBL] [Abstract][Full Text] [Related]
17. Virus-Like Particles Presenting the FGF-2 Protein or Identified Antigenic Peptides Promoted Antitumor Immune Responses in Mice.
Shu C; Sun P; Xie H; Huang W; Qi J; Ma Y
Int J Nanomedicine; 2020; 15():1983-1996. PubMed ID: 32308382
[TBL] [Abstract][Full Text] [Related]
18. Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors.
Nair RE; Kilinc MO; Jones SA; Egilmez NK
J Immunol; 2006 Jun; 176(12):7325-34. PubMed ID: 16751376
[TBL] [Abstract][Full Text] [Related]
19. Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8
Xiang SD; Wilson KL; Goubier A; Heyerick A; Plebanski M
Front Immunol; 2018; 9():2968. PubMed ID: 30631324
[TBL] [Abstract][Full Text] [Related]
20. Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.
Morisaki T; Hikichi T; Onishi H; Morisaki T; Kubo M; Hirano T; Yoshimura S; Kiyotani K; Nakamura Y
Immunol Invest; 2021 Jul; 50(5):562-579. PubMed ID: 32660279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
